Filing Flows › Health Care › International Stem Cell (ISCO)
International Stem Cell (ISCO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · International Stem Cell (ISCO) Q2 2026 earnings results →
Q2 2026 Revenue up 9% year over year to $2.7M · 3¢ of every $1 of revenue lost · operating margin -1.3%
International Stem Cell made $2.7M in Q2 2026 (+9% Y/Y): Biomedical Market $2.5M, Anti Aging Skincare Market $151K. Operating margin -1.3%, net loss $71K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.7M in Q2 2026, up 9% year over year and up 16% from the previous quarter. Biomedical Market was the largest line at 94% of revenue. Biomedical Market added $221K year over year (up 10%), 97% of the total change.
Operating costs exceeded revenue by $35K, an operating margin of -1.3%. Total costs grew 19% against revenue growth of 9%. The fastest-growing cost line was Cost of revenue (+31%). The quarter ended with a net loss of $71K, narrower than the previous quarter's $220K loss. Net interest and other expense of $36K was the main reason.
Operating cash flow was $167K. Non-cash charges added back $28K of depreciation and amortization and $59K of share-based compensation. Working capital and other items added $151K. Capital expenditures of $7K left free cash flow of $160K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $2.7M | +9% | -1.3% | −$71K | $167K |
| Q1 2026 | 10-Q | May 14, 2026 | $2.3M | +9% | -8.2% | −$220K | $121K |
| Q4 2025 | 10-K | Mar 30, 2026 | $2.2M | -12% | -14.5% | −$348K | $32K |
| Q3 2025 | 10-Q | Nov 13, 2025 | $2.4M | +9% | 4.0% | $57K | $49K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $2.4M | +5% | 6.8% | $129K | −$300K |
| Q1 2025 | 10-Q | May 14, 2025 | $2.1M | 0% | -10.1% | −$256K | $227K |
| Q4 2024 | 10-K | Mar 28, 2025 | $2.4M | +30% | 2.1% | $11K | −$74K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About International Stem Cell
International Stem Cell Corporation (sometimes referred to herein as “ISCO”, the “Company”, “we”, “us”, or “our”) is a clinical stage biotechnology company focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities and two revenue-generating businesses offering potential for increased future revenue. We currently have no revenue generated from our principal operations in therapeutic and clinical product development through research and development efforts. We have generated revenue from our two commercial businesses, anti-aging and research products, of a total of $9.1 million and $9.1 million for the years ended December 31, 2025 and 2024, respectively.
In its own words, from its 10-K, filed Mar 30, 2026.
International Stem Cell against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +9%. Operating margin: -1.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ISCO International Stem Cell | Q2 2026 | $2.7M | +9% | -1.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: International Stem Cell 10-Q on SEC EDGAR · CIK 1355790 · Pharmaceutical Preparations
More on ISCO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results
- International Stem Cell operating margin by quarter
- International Stem Cell net income by quarter
- International Stem Cell free cash flow by quarter
- International Stem Cell R&D spending by quarter
- International Stem Cell capital expenditures by quarter
- International Stem Cell Biomedical Market revenue by quarter
- International Stem Cell Anti Aging Skincare Market revenue by quarter